nystatin-a1 and Pruritus

An open, prospective, randomized pilot study was performed to assess the efficacy and safety of oral fluconazole 3 mg/kg once daily compared with oral nystatin 50,000 units/kg/day in four divided doses in preventing candida infections in 50 children undergoing remission induction or consolidation therapy for cancer. In 21 of 25 fluconazole-treated and 20 of 25 nystatin-treated patients the overall outcome of prophylaxis was clearly successful. Mild and transient oropharyngeal candidosis was observed in two and three patients in the fluconazole and nystatin groups respectively. One patient randomized to fluconazole and two patients randomized to nystatin required empirical treatment with amphotericin B and one patient assigned to fluconazole developed tissue-proven candida colitis. Initially non-colonized patients remained yeast-free throughout treatment with no differences between the two study arms. Initially colonized patients stayed colonized throughout treatment although at the end of the study, more patients randomized to nystatin were still harbouring yeasts (P = 0.05). Almost exclusively, Candida albicans (95%) was isolated. A change in species was observed in one patient in each arm of the study. Candida krusei or Candida glabrata were not encountered. Transient elevations of hepatic transaminases were more common in the fluconazole group, although not statistically significant (28% vs 12%, P = 0.15). Reversible grade I gastrointestinal and skin symptoms were observed in four patients randomized to fluconazole (16 vs 0%, P < 0.05). Fluconazole was as safe and effective as nystatin in controlling yeast colonization and in preventing superficial and invasive candida infections and the empirical use of amphotericin B in children and adolescents undergoing intensive chemotherapy for cancer.

Topics: Adolescent; Antifungal Agents; Antineoplastic Agents; Candida albicans; Candidiasis; Child; Child, Preschool; Feces; Female; Fluconazole; Humans; Infant; Male; Neoplasms; Nystatin; Oropharynx; Prospective Studies; Pruritus

Topics: Adult; Amphotericin B; Candidiasis; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Drug Evaluation; Exanthema; Female; Humans; Leukorrhea; Nystatin; Pregnancy; Pruritus

In a multicentre, double-blind, controlled trial of tetracycline plus nystatin (Mysteclin) and tetracycline, 111 patients with respiratory infections received one or other drug for a period of 10 days.The incidence of gastrointestinal symptoms was high in both groups before treatment began, and somewhat higher in the Mysteclin group than in the tetracycline group. After 10 days' treatment 50% of the patients in the Mysteclin group had symptoms, a mean of 1.44 each, compared with 34% of the patients in the tetracycline group, with a mean of 1.47 symptoms each; the difference between the two groups is not significant (P>0.05). The incidence of Candida albicans in the stools at 10 days in the Mysteclin group (9.1%) was significantly lower than that in the tetracycline group (37.1%), but this was not reflected in any reduction in the frequency of gastrointestinal symptoms.

Topics: Candida; Clinical Trials as Topic; Diarrhea; Feces; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Nystatin; Pruritus; Respiratory Tract Infections; Sex Factors; Tetracycline

Topics: Dermatologic Agents; Drug Combinations; Female; Hemorrhoids; Humans; Male; Neomycin; Nystatin; Proctitis; Pruritus; Triamcinolone Acetonide